MK-677 (Ibutamoren) and MOTS-c Stack: Complete Protocol for Women

What This Stack Is and Why Women Are Using It

Women using peptide protocols for metabolic health, body composition, and longevity are increasingly asking about combining MK-677 with MOTS-c. The appeal is logical on paper. MK-677 raises growth hormone (GH) and insulin-like growth factor-1 (IGF-1) by mimicking ghrelin at the GHS-R1a receptor, while MOTS-c, a peptide encoded in mitochondrial DNA, activates AMP-activated protein kinase (AMPK) and appears to counteract age-related metabolic decline.

The two compounds target different pathways. That separation is part of why practitioners pair them. But women are not small men, and the hormonal context that defines your reproductive stage changes how both compounds behave.

What MK-677 (Ibutamoren) Actually Does

MK-677 is a non-peptide ghrelin mimetic taken orally. Unlike injectable GH, it works by stimulating your pituitary to release GH in a pulsatile pattern. In a 32-patient, two-year placebo-controlled trial in older adults, MK-677 at 25 mg daily increased IGF-1 by roughly 60% and improved lean body mass without significant change in fat mass. That trial was conducted primarily in men, which limits how directly you can apply those numbers to a perimenopausal or postmenopausal woman whose estrogen-dependent GH pulsatility is already disrupted.

GH secretion in women is naturally higher than in men during reproductive years, driven partly by estrogen. After menopause, GH pulse amplitude drops sharply. MK-677 may partially restore GH output, but the magnitude of that effect in postmenopausal women compared with men is not well characterized in head-to-head data.

What MOTS-c Actually Does

MOTS-c (mitochondrial open reading frame of the 12S rRNA-c) is a 16-amino-acid peptide produced inside mitochondria. It regulates nuclear gene expression and appears to improve glucose uptake and fatty acid metabolism via AMPK activation. In a mouse study published in Cell Metabolism, MOTS-c administration reversed diet-induced insulin resistance and obesity. Circulating MOTS-c levels decline with age and with insulin resistance in humans, which has sparked interest in exogenous supplementation.

A 2019 human study found that circulating MOTS-c concentrations are significantly lower in older adults and in individuals with type 2 diabetes, suggesting a physiological relevance beyond animal models. Direct RCT evidence in women is absent.

Why Women Are a Distinct Population for This Stack

The combination is not studied in women as a defined group. Both compounds touch systems that are tightly regulated by estrogen, progesterone, and the menstrual cycle. Ignoring that context would be a clinical mistake.

Hormonal Cycles and GH Sensitivity

During the luteal phase of your cycle, progesterone mildly suppresses GH sensitivity. Estrogen, by contrast, amplifies GH pulse amplitude. That means the same MK-677 dose may produce a different IGF-1 response depending on where you are in your cycle or whether you are on hormonal contraception. No published trial has mapped this variation in women taking MK-677. This is a real evidence gap, not a theoretical one.

PCOS Considerations

Women with PCOS already have elevated GH pulsatility and frequently elevated IGF-1 in some studies. Adding MK-677 in a PCOS context requires particular caution. Elevated IGF-1 is associated with hyperandrogenism in PCOS, and PCOS affects 6-12% of women of reproductive age in the United States. Stacking a GH secretagogue on top of an already-dysregulated GH/IGF-1 axis is not straightforward. MOTS-c's insulin-sensitizing mechanism could, in theory, offer a benefit given the insulin resistance common in PCOS, but this has not been tested in a PCOS-specific trial.

Perimenopause and Postmenopause

The metabolic shift in perimenopause, including central fat redistribution, declining lean mass, and worsening insulin sensitivity, is exactly what practitioners hope to address with this combination. The rationale is plausible. The Menopause Society notes that body composition changes in menopause include increases in total and visceral fat mass independent of aging. If MOTS-c improves AMPK-mediated glucose disposal and MK-677 supports lean mass retention, the combination could address two distinct pathways driving this shift.

The problem is fluid retention. MK-677 causes dose-dependent fluid retention, and postmenopausal women already have altered aldosterone sensitivity and reduced estrogen-mediated vascular tone. Starting at 10 mg instead of 25 mg is a prudent approach in this group.

The Evidence Gap: What Is Known Versus What Is Extrapolated

The table below is the clearest way to show where the evidence actually stands for this stack in women. Most competitors present this combination as though the data is settled. It is not.

| Claim | Evidence Level | Source Type | Applies to Women Directly? | |---|---|---|---| | MK-677 raises IGF-1 | Strong | RCT (mixed-sex, older adults) | Partially: sex-stratified data sparse | | MK-677 improves lean mass | Moderate | RCT (mostly male) | Extrapolated | | MOTS-c reverses insulin resistance | Moderate | Mouse RCT | Not in humans yet | | MOTS-c is lower in older/diabetic humans | Moderate | Observational human study | Yes (men and women included) | | This specific combination improves body composition | None | Practitioner/patient report only | No human trial data | | The stack is safe in women | None | No formal safety study | No |

The honest clinical answer: this stack is being used ahead of its evidence. That does not automatically make it wrong for every woman, but it does mean your decision must rest on individual context, careful monitoring, and a prescribing clinician who tracks IGF-1, fasting glucose, and HbA1c.

Complete Protocol: Doses, Timing, and Cycling

Starting Doses for Women

Women metabolize both compounds differently from men, and the male-derived standard doses used in early MK-677 trials should not be your default starting point.

MK-677: Start at 10 mg orally, taken at night. Nighttime dosing aligns with your natural GH pulse and may reduce daytime fatigue and hunger. The commonly cited 25 mg dose comes from male-predominant studies and carries a higher side-effect burden, particularly for fluid retention and fasting glucose elevation, in women without a gradual titration period.

MOTS-c: Practitioner-reported protocols typically use 5 mg subcutaneous injection, 2 to 3 times per week. There is no dose-finding RCT in humans. Some protocols use 10 mg 2x weekly. Lower frequency tends to be used in women new to injectables or those with lower body weight.

Timing and Stacking Logic

Take MK-677 orally, 30 minutes before sleep. MOTS-c injections can be administered on non-consecutive days, subcutaneously in the abdomen or thigh. There is no pharmacokinetic interaction data between the two compounds, because this combination has not been formally studied. The timing protocol described here is derived from mechanism (avoid competing insulin-sensitivity signals around the same meal) and practitioner convention, not from a trial.

A reasonable morning protocol for MOTS-c injection days: inject MOTS-c in the morning, at least 2 hours before your first meal. MK-677 continues at night regardless of MOTS-c injection days.

Cycle Length

Most practitioners use MK-677 in 3-to-6-month cycles with a 4-to-8-week break. Continuous long-term use raises concerns about IGF-1 desensitization and sustained glucose dysregulation. MOTS-c cycle data in humans is absent; 8-to-12-week cycles are the most commonly reported pattern in practitioner communities, again without RCT support.

Monitoring

At baseline and every 4-6 weeks, track:

• Fasting insulin and glucose (MK-677 increases insulin resistance in some women)
• IGF-1 (target: age-adjusted upper-normal range, not supraphysiologic)
• HbA1c if you have pre-diabetes, PCOS, or are postmenopausal
• Weight and waist circumference (fluid retention can mask true fat vs. Lean changes)
• Blood pressure (fluid retention from MK-677)

A study published in the Journal of Clinical Endocrinology and Metabolism found that ibutamoren at 25 mg increased fasting blood glucose significantly in older adults after 12 months, which is a particularly relevant signal for women with PCOS or perimenopausal insulin resistance.

Pregnancy, Lactation, and Contraception: Read This Section First

MK-677 is not safe during pregnancy. There are no human pregnancy safety data, and animal studies raise concern about GH-axis dysregulation during fetal development. GH and IGF-1 are essential regulators of placental function and fetal growth; exogenous stimulation of this axis during pregnancy carries theoretical teratogenic risk that cannot be dismissed. MK-677 should be discontinued before attempting conception and must not be used during pregnancy or breastfeeding.

MOTS-c human pregnancy data is completely absent. Zero studies have examined MOTS-c administration during human pregnancy. MOTS-c plays a role in mitochondrial function, which is foundational to early embryonic development. The absence of data is not reassurance. MOTS-c should be considered contraindicated in pregnancy until proven otherwise.

Contraception requirement: If you are of reproductive age and using either compound, use reliable contraception. Discuss your contraception method with your prescribing clinician, as hormonal contraceptives may alter GH sensitivity and IGF-1 levels, which could interact with MK-677 effects.

Lactation: Neither compound has lactation transfer data in humans. Until such data exists, both should be avoided during breastfeeding. The precautionary principle applies.

ACOG advises that any drug or supplement without adequate human pregnancy safety data should be avoided unless the clinical benefit clearly outweighs theoretical risk. Neither MK-677 nor MOTS-c clears that bar for pregnancy use.

Who This Stack May Be Right For (and Who Should Avoid It)

Potentially Appropriate Candidates

• Postmenopausal women with documented sarcopenia, stable metabolic labs, no personal or family history of hormone-sensitive cancer, and a monitoring-committed prescriber
• Women in their 40s with perimenopausal body composition changes who have tried lifestyle modification and want to explore adjunctive metabolic support under medical supervision
• Women with age-related decline in IGF-1 confirmed on lab testing (below the lower quartile for age)

The stack is less about "optimization" marketing and more about addressing a specific, measurable deficit. If your IGF-1 is already mid-range for your age, adding MK-677 is unlikely to produce meaningful benefit and adds unnecessary risk.

Women Who Should Not Use This Stack

• Pregnant women or those actively trying to conceive (see section above)
• Breastfeeding women
• Women with active or prior hormone-sensitive cancer (breast, ovarian, endometrial), given IGF-1's role in tumor promotion
• Women with uncontrolled type 2 diabetes or significant insulin resistance without medical supervision
• Women with PCOS who have elevated IGF-1 at baseline
• Women with active fluid-retention conditions, including heart failure or nephrotic syndrome
• Women under 25, whose GH axis is still physiologically active

A Note on Insulin Resistance and Metabolic Health

The MK-677 and MOTS-c combination presents a genuine internal tension for women with insulin resistance. MK-677 worsens insulin sensitivity through GH-mediated insulin antagonism. MOTS-c, via AMPK activation, may partially counteract that effect. Whether MOTS-c fully compensates for MK-677's glucose-elevating impact in women is unknown. IGF-1 and insulin share receptor signaling pathways, and adding a GH secretagogue in a woman with pre-existing insulin resistance requires careful glucose monitoring from day one.

Female-Relevant Conditions This Stack Touches

Osteoporosis and Bone Health

GH and IGF-1 stimulate osteoblast activity. A 12-month RCT of ibutamoren in older adults showed a modest improvement in bone mineral density markers, though this was in a predominantly male cohort. Postmenopausal women losing bone at roughly 1-2% per year after menopause represent a population where MK-677's IGF-1 effect could be mechanistically relevant to bone health, but this should not replace proven interventions like bisphosphonates or, where appropriate, hormone therapy.

Sarcopenia in Perimenopause and Beyond

Muscle mass declines accelerate around menopause. Women lose lean mass at approximately 0.5-1% per year after age 40, and that rate increases after menopause. MK-677's effect on lean mass retention is one of the more consistently reported benefits across the limited available data, even if most trials enrolled men.

Hormonal Acne and Androgen Sensitivity

Elevated IGF-1 stimulates sebaceous gland activity and may worsen acne, particularly in women with PCOS or androgen sensitivity. If you notice worsening skin symptoms on MK-677, this is a physiologically expected effect, not a coincidence. It is worth discussing dose reduction rather than adding a topical treatment on top of a compound that may be driving the problem.

Side Effects Specific to Women

Both compounds carry side effects that deserve sex-specific framing.

MK-677 side effects in women:

• Fluid retention: more symptomatic in women with cyclical fluid changes or perimenopause-related aldosterone shifts
• Increased appetite via ghrelin mimicry: the hunger signal is stronger and may conflict directly with caloric targets in women pursuing fat loss
• Fatigue and lethargy, particularly at doses above 10 mg in women new to the compound
• Glucose dysregulation: fasting glucose rise of 5-10 mg/dL has been reported at 25 mg in older adults
• Potential IGF-1-mediated androgenic effects including acne and mild hair thinning

MOTS-c side effects:

• Injection site reactions (erythema, mild swelling)
• Headache reported in practitioner case series
• Hypoglycemia risk is theoretical given AMPK activation but has not been reported at typical doses in the available literature

Regulatory and Sourcing Realities

Neither MK-677 nor MOTS-c is FDA-approved for any indication in women. MK-677 has been studied in clinical trials and is not approved for human therapeutic use outside of those trials. The FDA has issued warnings about unapproved peptide products being sold through compounding pharmacies and research chemical suppliers. MOTS-c is not available as an approved drug anywhere in the world.

Sourcing from an accredited compounding pharmacy working under a clinician's prescription is the minimum quality standard. Third-party batch testing for purity and sterility is non-negotiable for injectable compounds like MOTS-c. Peptides bought without a prescription from research chemical websites carry contamination, mislabeling, and dosing accuracy risks that make any protocol unreliable.

What a Prescribing Clinician Needs to Know

If you bring this stack to your clinician, these are the specific questions worth addressing together:

1. What is your baseline fasting glucose, insulin, HbA1c, and IGF-1?
2. What is your current hormonal status (reproductive years, perimenopause, postmenopause, on HRT)?
3. Do you have PCOS, a personal or family history of breast or ovarian cancer, or active metabolic disease?
4. What is your contraception status if you are of reproductive age?
5. Who is sourcing these compounds and how is purity verified?

As WomanRx reviewer Maya Okafor, MD, notes: "The mechanistic rationale for this combination in perimenopausal women is genuinely interesting, but the absence of sex-stratified safety data means I need baseline labs, a monitoring plan, and a very clear conversation about what we don't know before I'd support a patient using both compounds together."